High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: Long-term results of the German AMLCG

Leukemia

Volumn 23, Issue 12, 2009, Pages 2248-2258

  Lengfelder, E ^a   Haferlach, C ^b   Saussele, S ^a   Haferlach, T ^b   Schultheis, B ^a   Schnittger, S ^b   Ludwig, W D ^c   Staib, P ^d   Aul, C ^e   Gruneisen A ^f   Kern, W ^b   Reichle, A ^g   Serve, H ^h   Berdel, W E ^h   Braess, J ⁱ   Spiekermann, K ⁱ   Wormann B ^j   Sauerland, M C ^k   Heinecke, A ^k   Hiddemann, W ⁱ   Hehlmann, R ^a   Buchner T ^h   more..

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b MLL MUNICH LEUKEMIA LABORATORY   (Germany)

^c HUMBOLDT UNIVERSITY   (Germany)

^d UNIVERSITY OF COLOGNE   (Germany)

^e ST JOHANNES HOSPITAL   (Germany)

^f VIVANTES KLINIKUM NEUKÖLLN   (Germany)

^g UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^h UNIVERSITY HOSPITAL MÜNSTER   (Germany)

ⁱ LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^j KLINIKUM BRAUNSCHWEIG   (Germany)

^k UNIVERSITY OF MÜNSTER   (Germany)

more..

Author keywords

acute promyelocytic leukemia; high dose cytosine arabinoside; relapse rate; white blood cell count

Indexed keywords

ANTINEOPLASTIC AGENT; CYTARABINE; RETINOIC ACID;

ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; GERMANY; HUMAN; LONGITUDINAL STUDY; LYMPHOCYTE COUNT; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; REMISSION; SURVIVAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; GERMANY; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; LONGITUDINAL STUDIES; LYMPHOCYTE COUNT; MIDDLE AGED; PROGNOSIS; REMISSION INDUCTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TRETINOIN; YOUNG ADULT;

EID: 74049115852     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2009.183     Document Type: Article

References (36)

1. Estey E, Thall S, Pierce S, Kantarjian H, Keating M. Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine. J Clin Oncol 1997; 15: 483-490. (Pubitemid 27074214)
2. Sanz M, Montesinos P, Vellenga E, Rayón C, de la Serna J, Parody R et al. Risk-adapted therapy of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA group. Blood 2008; 112: 3130-3134.
3. Sanz M, Grimwade D, Tallman M, Lowenberg B, Fenaux P, Estey E et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009; 113: 1875-1891.
4. Sanz MA, Lo-Coco F, Martin G, Avvisati G, Rayón C, Barbui T et al. Definition of relapse risk and role of non-anthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 2000; 96: 1247-1252.
5. Burnett AK, Grimwade D, Solomon E, Wheatley K, Goldstone A. Presenting white blood cell counts and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: results of the randomized MRC trial. Blood 1999; 93: 4131-4143. (Pubitemid 29279255)
6. Fenaux P, Chastang C, Chevret S, Sanz M, Dombet H, Archimbaud E et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. Blood 1999; 94: 1192-1200. (Pubitemid 29380399)
7. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Woods WG et al. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood 2002; 100: 4298-4302. (Pubitemid 36001941)
8. Asou N, Kishimoto Y, Okada M, Kawai Y, Tsuzuki M, Horikawa K et al. A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML/RARA transcript after consolidation therapy: the Japan Adult Leukemia Study Group (JALSG) APL97 study. Blood 2007; 110: 59-66. (Pubitemid 47026819)
9. Lo-Coco F, Avvisati G, Vignetti M, Fioritoni G, Liso V, Ferrara F et al. Front-line therapy of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation: results of the AIDA-2000 trial of the Italian GIMEMA Group. Blood 2004; 104. (abstract [392]).
10. Powell BL. Effect of consolidation with arsenic trioxide (As2O3) on event-free survival (EFS) and overall survival (OS) among patients with newly diagnosed acute promyelocytic leukemia (APL): North American Intergroup Protocol C9710. J Clin Oncol 2007; 25 (suppl, abstract [2]).
11. Ades L, Sanz M, Chevret S, Montesinos P, Chevallier P, Raffoux E et al. Treatment of newly diagnosed acute promyelocytic leukemia(APL): a comparison of the French-Belgian-Swiss and the PETHEMA results. Blood 2008; 111: 1078-1084. (Pubitemid 351213385)
12. Ades L, Chevret S, Raffoux E, Guerci A, Pigneux A, Stoppa AM et al. Is cytarabin useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group. J Clin Oncol 2006; 24: 5703-5710. (Pubitemid 46631312)
13. Sanz M, Montesinos P, Holowieka A, Milone G, Rayon C, de Lisa E et al. Risk-adapted treatment of acute promyelocytic leukemia: results of the PETHEMA LPA2005 trial using all-trans retinoic acid and anthracycline with cytarabine for high risk patients. Blood 2008; 112 (abstract [138]).
14. Büchner T, Hiddemann W, Wörmann B, Lö ffler H, Gassmann W, Haferlach T et al. Double induction strategy for acute myeloid leukemia. The effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine. A randomized trial by the German AML Cooperative Group. Blood 1999; 93: 4116-4124. (Pubitemid 29279253)
15. Lengfelder E, Reichert A, Hehlmann R, Lö ffler H, Fonatsch C, Schoch C et al. Effects of high dose cytarabin as part of double induction strategy in acute promyelocytic leukemia and results of combination with all-trans retinoic acid. Blood 1997; 90 (abstract [1475]).
16. Fenaux P, Le Deley MC, Castaigne S, Archimbaud E, Chomienne C, Link H et al. Effect of all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized study. Blood 1993; 82: 3241-3249. (Pubitemid 23356690)
17. Frankel SR, Eardley A, Heller G, Berman E, Miller WH, Dmitrowsky E et al. All-trans retinoic acid for acute promyelocytic leukemia. Results of the New York Study. Ann Intern Med 1994; 120: 278-286. (Pubitemid 24050023)
18. Meloni G, Diviero D, Vignetti M, Avvisati G, Capria S, Petti MC et al. Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission: prognostic relevance of pretransplant minimal residual disease assessment by reverse transcription polymerase chain reaction of the PML/RARa fusion gene. Blood 1997; 90: 1321-1325. (Pubitemid 27314172)
19. Lengfelder E, Reichert A, Schoch C, Haase D, Haferlach T, Löffler H et al. Double induction strategy including high dose cytarabin in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. Leukemia 2000; 14: 1362-1370. (Pubitemid 30601354)
20. Cheson BD, Bennet JM, Kopecky KJ, Büchner T, Willman CL, Estey E et al. Revised recommendation of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003; 21: 4642-4649. (Pubitemid 46594039)
21. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representation of old estimators. Stat Med 1999; 18: 695-706. (Pubitemid 29126745)
22. Cox DR. Regression models and life-tables (with discussion). J R Stat Soc B 1972; 34: 187-202.
23. Kaplan EL, Meier P. Non-parametric estimation from incomplete observation. J Am Stat Assoc 1958; 53: 457-481.
24. Hiddemann W, Kreutzmann H, Straif K, Ludwig WD, Mertelsmann R, Donhuijsen-Ant R et al. High dose cytosine arabinoside and mitoxantrone. A highly effective regimen in refractory acute myeloid leukemia. Blood 1987; 69: 744-749. (Pubitemid 17057450)
25. Hiddemann W. Cytosine arabinoside in the treatment of acute myeloid leukemia: the role and place of high-dose regimens. Ann Hematol 1991; 62: 119-128.
26. Casazza AM, Pratesi G, Giulani F, Di Marco A. Antileukemic activity of 4-demethoxydaunorubicine in mice. Tumori 1980; 66: 549-564.
27. De Witte T, Suciu S, Zittoun R, Resegotti L, Liso V, Willemze R et al. The type of anthracycline administered during remission induction and consolidation therapy of AML has an impact on feasibility of subsequent autologous or allogeneic transplantation and induced marrow toxicity: preliminary results of the EORTC-GIMEMA AML-10 randomized trial. Blood 2000; 96 (abstract [2167]).
28. Lobe I, Rigal-Huguet F, Vekhoff A, Desablens B, Bordessoule D, Mounier C et al. Myelodysplastic syndrome after acute promyelocytic leukemia: the European APL group experience. Leukemia 2003; 17: 1600-1604. (Pubitemid 36986963)
29. Lataglia R, Petti M, Fenu S, Mancini M, Spiriti M, Breccia M et al. Therapy-related myelodysplastic syndromeFacute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem. Blood 2002; 99: 822-824. (Pubitemid 34525541)
30. De la Serna J, Montesinos P, Velenga E, Rayón C, Parody R, León A et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicine. Blood 2008; 111: 3395-3402.
31. Di Bona E, Avvisati G, Castaman G, Luce Vegna M, De Sanctis V, Rodeghiero F et al. Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukemia. Br J Haematol 2000; 108: 689-695. (Pubitemid 30304497)
32. Yanada M, Matsushita T, Asou N, Kishimoto Y, Tsuzuki M, Maeda Y et al. Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors and influence on outcome. Eur J Haematol 2007; 78: 213-219.
33. Vahdat L, Maslak P, Miller WH, Eardley A, Heller G, Scheinberg DA et al. Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PML/RARa isoform, and CD 13 expression in patients treated with all-trans retinoic acid. Blood 1994; 84: 3843-3849.
34. De Botton S, Dombret H, Sanz M, San Miguel J, Caillot D, Zittoun R et al. Incidence, clinical features and outcome of all-trans acid retinoid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. Blood 1998; 92: 2712-2718. (Pubitemid 28469083)
35. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A et al. Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. Blood 2000; 95: 90-95. (Pubitemid 30017230)
36. Montesinos P, Bergua J, Vellenga E, Rayón C, Parody R, de la Serna J et al. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome and prognostic factors. Blood 2009; 113: 775-783.